Back to all news

AI Model Predicts Pluvicto Response in Prostate Cancer via PSMA-PET

AuntMinnieIndustry

A multimodal AI algorithm predicts response to Pluvicto therapy in mCRPC patients using PSMA-PET imaging and lab data.

Key Details

  • 1Researchers developed an AI model combining PSMA-PET imaging features with routine lab values to predict Pluvicto response in metastatic castration-resistant prostate cancer (mCRPC).
  • 2The retrospective analysis included 302 mCRPC patients with evaluable pretreatment PSMA-PET scans and at least three cycles of Pluvicto therapy.
  • 3Key imaging features included lesion shape, standardized uptake value (SUV) metrics, and uptake heterogeneity.
  • 4Ten laboratory parameters, such as PSA and lymphocyte count, were included from the EHR.
  • 5The combined model achieved an area under the curve (AUC) of 0.80, outperforming models using only clinical (AUC 0.73) or only imaging features (AUC 0.76).
  • 6Responders identified by the model showed much higher 30-month survival (79%) than nonresponders (34%).

Why It Matters

This research highlights the potential for AI-driven, multimodal decision support to personalize radioligand therapy in prostate cancer. Accurate prediction of treatment response could improve patient selection and outcomes in high-impact oncology workflows.

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.